Achillion Pharmaceuticals, Inc.

Description

• Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) is a science-driven, patient-focused company leveraging its strengths across the continuum from drug discovery to commercialization to provide better treatments for people with serious diseases.Achillions rational, iterative approach to discovery and development has created a powerful engine for advancing novel small-molecule drugs. Achillion pairs this rigorous science with insights about patients, caregivers, and the healthcare market to choose product candidates with disruptive potential or the potential to change treatment paradigms. This has already enabled Achillion to generate three clinical-stage oral chronic hepatitis C (HCV) candidates and a proprietary library of over 1,300 potent and specific complement inhibitors.The companys commitments to scientific excellence and market impact are reinforced by a culture that encourages cross-functional collaboration, organizational nimbleness and resilience, professional courage, and informed risk-taking.By combining great science, a growing commercial capability, and a keen understanding of patient needs, Achillion is rapidly becoming a fully-integrated commercial pharmaceutical company capable of bringing its factor D inhibitors to patients with rare diseases on its own.Achillion is headquartered in New Haven, Connecticut. The companys common stock trades on the NASDAQ Global Select Market under the symbol: ACHN.
• 

  Headquarters:1777 Sentry Parkway West , Blue Bell, Pennsylvania, United States

  More
• 

  Phone Number: +1 215-709-3040

• 

  Website: https://www.achillion.com

• 

  Employees:64

• 

  Revenue:$10 - 50M

• 

  Legal Name:Achillion Pharmaceuticals, Inc.

• Achillion Pharmaceuticals, Inc.'s Social Media

  
• Is this data correct?

• |  NAICS Code: 325412  |

  Show More